BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calderaro J, Ziol M, Paradis V, Zucman-rossi J. Molecular and histological correlations in liver cancer. Journal of Hepatology 2019;71:616-30. [DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Evangelista EB, Kwee SA, Sato MM, Wang L, Rettenmeier C, Xie G, Jia W, Wong LL. Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics. Diagnostics (Basel) 2019;9:E167. [PMID: 31671805 DOI: 10.3390/diagnostics9040167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
3 Hirsch TZ, Negulescu A, Gupta B, Caruso S, Noblet B, Couchy G, Bayard Q, Meunier L, Morcrette G, Scoazec JY, Blanc JF, Amaddeo G, Nault JC, Bioulac-Sage P, Ziol M, Beaufrère A, Paradis V, Calderaro J, Imbeaud S, Zucman-Rossi J. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. J Hepatol 2020;72:924-36. [PMID: 31862487 DOI: 10.1016/j.jhep.2019.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
4 Zou C, El Dika I, Vercauteren KOA, Capanu M, Chou J, Shia J, Pilet J, Quirk C, Lalazar G, Andrus L, Kabbani M, Yaqubie A, Khalil D, Mergoub T, Chiriboga L, Rice CM, Abou‐alfa GK, de Jong YP. Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine. [DOI: 10.1002/cam4.4375] [Reference Citation Analysis]
5 Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int 2021;21:409. [PMID: 34344378 DOI: 10.1186/s12935-021-02108-2] [Reference Citation Analysis]
6 Liao H, Long Y, Han R, Wang W, Xu L, Liao M, Zhang Z, Wu Z, Shang X, Li X, Peng J, Yuan K, Zeng Y. Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma. Clin Transl Med 2020;10:e102. [PMID: 32536036 DOI: 10.1002/ctm2.102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Calaf GM, Crispin LA, Muñoz JP, Aguayo F, Bleak TC. Muscarinic Receptors Associated with Cancer. Cancers 2022;14:2322. [DOI: 10.3390/cancers14092322] [Reference Citation Analysis]
8 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
9 He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother 2020;132:110851. [PMID: 33080466 DOI: 10.1016/j.biopha.2020.110851] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Chen C, Lv Q, Li Y, Jin YH. The Anti-Tumor Effect and Underlying Apoptotic Mechanism of Ginsenoside Rk1 and Rg5 in Human Liver Cancer Cells. Molecules 2021;26:3926. [PMID: 34199025 DOI: 10.3390/molecules26133926] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Hobeika C, Nault JC, Barbier L, Schwarz L, Lim C, Laurent A, Gay S, Salamé E, Scatton O, Soubrane O, Cauchy F. Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis. JHEP Rep 2020;2:100153. [PMID: 32995713 DOI: 10.1016/j.jhepr.2020.100153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Katabathina VS, Marji H, Khanna L, Ramani N, Yedururi S, Dasyam A, Menias CO, Prasad SR. Decoding Genes: Current Update on Radiogenomics of Select Abdominal Malignancies. Radiographics 2020;40:1600-26. [PMID: 33001791 DOI: 10.1148/rg.2020200042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li X, Yao Q, Liu C, Wang J, Zhang H, Li S, Cai P. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? JHC 2022;Volume 9:379-87. [DOI: 10.2147/jhc.s364742] [Reference Citation Analysis]
14 Shi JY, Wang X, Ding GY, Dong Z, Han J, Guan Z, Ma LJ, Zheng Y, Zhang L, Yu GZ, Wang XY, Ding ZB, Ke AW, Yang H, Wang L, Ai L, Cao Y, Zhou J, Fan J, Liu X, Gao Q. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut 2021;70:951-61. [PMID: 32998878 DOI: 10.1136/gutjnl-2020-320930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Yu B, Liang H, Ye Q, Wang Y. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection. J Gastrointest Surg 2021;25:112-24. [PMID: 32128678 DOI: 10.1007/s11605-020-04554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Oropeza CE, Ondracek CR, Tarnow G, Maienschein-Cline M, Green SJ, McLachlan A. Heterogeneous phenotypes of Pten-null hepatocellular carcinoma in hepatitis B virus transgenic mice parallels liver lobule zonal gene expression patterns. Virology 2022;566:16-25. [PMID: 34844082 DOI: 10.1016/j.virol.2021.11.007] [Reference Citation Analysis]
17 Li M, Deng Y, Zhuo M, Zhou H, Kong X, Xia X, Su Z, Chen Q, Guo P, Mo P, Yu C, Li W. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression. Theranostics 2020;10:8863-79. [PMID: 32754284 DOI: 10.7150/thno.45581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Feng S, Yu X, Liang W, Li X, Zhong W, Hu W, Zhang H, Feng Z, Song M, Zhang J, Zhang X. Development of a Deep Learning Model to Assist With Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:762733. [DOI: 10.3389/fonc.2021.762733] [Reference Citation Analysis]
19 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
20 Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatol Res 2021;51:5-18. [DOI: 10.1111/hepr.13539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
21 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
22 Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Hum Pathol 2021;113:39-46. [PMID: 33905775 DOI: 10.1016/j.humpath.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Loesch R, Caruso S, Paradis V, Godard C, Gougelet A, Renault G, Picard S, Tanaka I, Renoux-martin Y, Perret C, Taketo MM, Zucman-rossi J, Colnot S. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.023] [Reference Citation Analysis]
24 Liao H, Xiong T, Peng J, Xu L, Liao M, Zhang Z, Wu Z, Yuan K, Zeng Y. Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning. Ann Surg Oncol. 2020;27:2359-2369. [PMID: 31916093 DOI: 10.1245/s10434-019-08190-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
25 Sun J, Chen Q, Ma J. Notch–Sox9 Axis Mediates Hepatocyte Dedifferentiation in KrasG12V-Induced Zebrafish Hepatocellular Carcinoma. IJMS 2022;23:4705. [DOI: 10.3390/ijms23094705] [Reference Citation Analysis]
26 Cui Y, Li H, Zhan H, Han T, Dong Y, Tian C, Guo Y, Yan F, Dai D, Liu P. Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics. Front Oncol 2021;11:733478. [PMID: 34604069 DOI: 10.3389/fonc.2021.733478] [Reference Citation Analysis]
27 Zeisel MB, Guerrieri F, Levrero M. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:1715. [PMID: 33923385 DOI: 10.3390/jcm10081715] [Reference Citation Analysis]
28 Kim H, Jang M, Park YN. Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors. J Liver Cancer 2020;20:17-24. [DOI: 10.17998/jlc.20.1.17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Xu P, Luo A, Xiong C, Ren H, Yan L, Luo Q. SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway. Cancer Cell Int 2022;22:1. [PMID: 34980127 DOI: 10.1186/s12935-021-02402-z] [Reference Citation Analysis]
30 Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Reference Citation Analysis]
31 Karadag Soylu N. Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer 2020;51:1176-86. [PMID: 32844348 DOI: 10.1007/s12029-020-00499-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
32 Fang Y, Yang Y, Li N, Zhang XL, Huang HF. Emerging role of long noncoding RNAs in recurrent hepatocellular carcinoma. World J Clin Cases 2021; 9(32): 9699-9710 [PMID: 34877309 DOI: 10.12998/wjcc.v9.i32.9699] [Reference Citation Analysis]
33 Krinsky G, Shanbhogue K. Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical and Imaging Implications. Radiology 2021;300:583-5. [PMID: 34227887 DOI: 10.1148/radiol.2021211316] [Reference Citation Analysis]
34 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
35 Liu Y, Li YQ, Huang SH, Li YL, Xia JW, Jia JS, Wei F, Wang JH, Dai GQ, Wang YC, Li XY, Han LX, Zhang XL, Xiang XD, Zhao WT, Xiao D, Lin XL. Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways. Aging (Albany NY) 2021;13:21155-90. [PMID: 34517344 DOI: 10.18632/aging.203402] [Reference Citation Analysis]
36 Samdanci ET, Akatli AN, Soylu NK. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1187-92. [PMID: 32860202 DOI: 10.1007/s12029-020-00500-1] [Reference Citation Analysis]
37 Huang T, Yan T, Chen G, Zhang C. Development and Validation of a Gene Mutation-Associated Nomogram for Hepatocellular Carcinoma Patients From Four Countries. Front Genet 2021;12:714639. [PMID: 34621291 DOI: 10.3389/fgene.2021.714639] [Reference Citation Analysis]
38 Kaushik AC, Mehmood A, Wei DQ, Dai X. Robust Biomarker Screening Using Spares Learning Approach for Liver Cancer Prognosis. Front Bioeng Biotechnol 2020;8:241. [PMID: 32318552 DOI: 10.3389/fbioe.2020.00241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Morales S, Engan K, Naranjo V. Artificial intelligence in computational pathology – challenges and future directions. Digital Signal Processing 2021;119:103196. [DOI: 10.1016/j.dsp.2021.103196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Tsai J, Jeng Y, Lee C, Liau J. Molecular features of primary hepatic undifferentiated carcinoma. Mod Pathol. [DOI: 10.1038/s41379-021-00970-z] [Reference Citation Analysis]
41 Liu X, He Y, Wang P, Hu J, Hao C, Wang Q, Yang Y, Sun Y, Ma B, Sun H, Xue D, Meng X, Ashraf G. ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-25. [DOI: 10.1155/2022/5791471] [Reference Citation Analysis]
42 Kang HJ, Kim H, Lee DH, Hur BY, Hwang YJ, Suh KS, Han JK. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology 2021;:204352. [PMID: 34227881 DOI: 10.1148/radiol.2021204352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 He Z, Peng C, Li T, Li J. Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma. Front Genet 2022;13:858905. [DOI: 10.3389/fgene.2022.858905] [Reference Citation Analysis]
44 Liu X, Liu Y, Liu Z, Zhang Y, Ma Y, Bai J, Yao H, Wang Y, Zhao X, Li R, Song X, Chen Y, Feng Z, Wang L. Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis. Biochem Biophys Rep 2021;28:101157. [PMID: 34754951 DOI: 10.1016/j.bbrep.2021.101157] [Reference Citation Analysis]
45 Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol 2022. [PMID: 35258675 DOI: 10.1007/s00330-022-08643-4] [Reference Citation Analysis]
46 Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zhang K, Fang T, Zhao D, Cen F, Yan X, Jin X. Circular RNA Circ_0008043 promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating the microRNA (miR)-326/RAB21 axis. Bioengineered 2022;13:6600-14. [DOI: 10.1080/21655979.2022.2044260] [Reference Citation Analysis]
48 Nahm JH, Park YN. [Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:268-83. [PMID: 34824185 DOI: 10.4166/kjg.2021.140] [Reference Citation Analysis]
49 Li HY, Yin FF, Li XY, Jia WN, Ding J, Zhang L, Wang ZH, Hu QQ, Zuo JL, Jia HL, Wang LH, Fan CH, Gu HZ, Wu J. Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma. Biosens Bioelectron 2021;174:112738. [PMID: 33257185 DOI: 10.1016/j.bios.2020.112738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
51 Okamura S, Shimose S, Niizeki T, Kamachi N, Noda Y, Shirono T, Iwamoto H, Nakano M, Kuromatsu R, Koga H, Torimura T. Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. Mol Clin Oncol 2022;16:8. [PMID: 34881028 DOI: 10.3892/mco.2021.2442] [Reference Citation Analysis]
52 Gerossier L, Dubois A, Paturel A, Fares N, Cohen D, Merle P, Lachuer J, Wierinckx A, Saintigny P, Bancel B, Selves J, Schnitzler A, Ouine B, Cartier A, de Koning L, Puard V, Bieche I, Hernandez-Vargas H, Hall J, Chemin I. PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel? Clin Res Hepatol Gastroenterol 2020;:101553. [PMID: 33183998 DOI: 10.1016/j.clinre.2020.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Caruso S, O’brien DR, Cleary SP, Roberts LR, Zucman‐rossi J. Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology 2021;73:14-26. [DOI: 10.1002/hep.31394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
54 Saillard C, Schmauch B, Laifa O, Moarii M, Toldo S, Zaslavskiy M, Pronier E, Laurent A, Amaddeo G, Regnault H, Sommacale D, Ziol M, Pawlotsky JM, Mulé S, Luciani A, Wainrib G, Clozel T, Courtiol P, Calderaro J. Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. Hepatology 2020;72:2000-13. [PMID: 32108950 DOI: 10.1002/hep.31207] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 32.0] [Reference Citation Analysis]
55 Shibata O, Kamimura K, Ko M, Sakai N, Abe H, Morita S, Mizusawa T, Sato H, Sakamaki A, Terai S. Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. Intern Med 2021;60:1709-15. [PMID: 33390501 DOI: 10.2169/internalmedicine.6580-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Yang W, Li Z, Qin R, Wang X, An H, Wang Y, Zhu Y, Liu Y, Cai S, Chen S, Sun T, Meng J, Yang C. YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA. Front Oncol 2019;9:1187. [PMID: 31799179 DOI: 10.3389/fonc.2019.01187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
57 Ridder DA, Weinmann A, Schindeldecker M, Urbansky LL, Berndt K, Gerber TS, Lang H, Lotz J, Lackner KJ, Roth W, Straub BK. Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma. Int J Cancer 2021. [PMID: 34894400 DOI: 10.1002/ijc.33898] [Reference Citation Analysis]
58 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
59 Wu Y, Yuan J, Tu Z, Chen H, Wu X. CircLATS2 Regulates miR-520a-3p/E2F7/p-VEGFR2 Signaling Pathway to Promote Hepatocellular Carcinoma Progression and Angiogenesis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/3744560] [Reference Citation Analysis]
60 Rakké YS, Sprengers D, Kwekkeboom J, IJzermans JNM. Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Ann Transl Med 2020;8:1614. [PMID: 33437813 DOI: 10.21037/atm-2020-115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Wu C, Qi X, Qiu Z, Deng G, Zhong L. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC. Aging (Albany NY) 2021;13:22148-63. [PMID: 34491228 DOI: 10.18632/aging.203494] [Reference Citation Analysis]
62 Ma XL, Hu B, Tang WG, Xie SH, Ren N, Guo L, Lu RQ. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol 2020;13:11. [PMID: 32024555 DOI: 10.1186/s13045-020-0845-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
63 Feng Z, Li H, Zhao H, Jiang Y, Liu Q, Chen Q, Wang W, Rong P. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. Radiology 2021;300:219-29. [PMID: 33973839 DOI: 10.1148/radiol.2021203614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhu C, Ho YJ, Salomao MA, Dapito DH, Bartolome A, Schwabe RF, Lee JS, Lowe SW, Pajvani UB. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J Hepatol 2021;74:613-26. [PMID: 33038431 DOI: 10.1016/j.jhep.2020.09.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
65 Koufaris C, Kirmizis A. Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes. Front Oncol 2021;11:691950. [PMID: 34150665 DOI: 10.3389/fonc.2021.691950] [Reference Citation Analysis]
66 Busche S, John K, Wandrer F, Vondran FWR, Lehmann U, Wedemeyer H, Essmann F, Schulze-Osthoff K, Bantel H. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death Dis 2021;12:736. [PMID: 34312366 DOI: 10.1038/s41419-021-04020-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Pavlović N, Calitz C, Thanapirom K, Mazza G, Rombouts K, Gerwins P, Heindryckx F. Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma. Elife 2020;9:e55865. [PMID: 33103995 DOI: 10.7554/eLife.55865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
68 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Hermida M, Preel A, Assenat E, Piron L, Cassinotto C, Ursic-Bedoya J, Guillot C, Herrero A, Panaro F, Pageaux GP, Guiu B. Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation. Hepatol Commun 2021;5:689-700. [PMID: 33860126 DOI: 10.1002/hep4.1661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Wang Q, Yu X, Zheng Z, Chen F, Yang N, Zhou Y. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. PeerJ 2021;9:e11342. [PMID: 33987018 DOI: 10.7717/peerj.11342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Chen W, Ou M, Tang D, Dai Y, Du W. Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma. J Immunol Res 2020;2020:5494858. [PMID: 32211443 DOI: 10.1155/2020/5494858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
72 Gielen AHC, Samarska I, Den Dulk M, Beckervordersandforth J, Dejong KHC, Bouwense SAW, Dewulf M. Osteoclast-like giant cells in hepatocellular carcinoma case description and review of the literature. Acta Chir Belg 2021;:1-7. [PMID: 34110978 DOI: 10.1080/00015458.2021.1940443] [Reference Citation Analysis]
73 Steiger K, Gross N, Widholz SA, Rad R, Weichert W, Mogler C. Genetically Engineered Mouse Models of Liver Tumorigenesis Reveal a Wide Histological Spectrum of Neoplastic and Non-Neoplastic Liver Lesions. Cancers (Basel) 2020;12:E2265. [PMID: 32823526 DOI: 10.3390/cancers12082265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Zhang Z, Yang G, Fan F, Zhong C, Yuan Y, Zhang X, Chang S. Terahertz circular dichroism sensing of living cancer cells based on microstructure sensor. Anal Chim Acta 2021;1180:338871. [PMID: 34538326 DOI: 10.1016/j.aca.2021.338871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Wong M, Kim JT, Cox B, Larson BK, Kim S, Waters KM, Vail E, Guindi M. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat Oncol 2021;8:HEP39. [PMID: 34765106 DOI: 10.2217/hep-2020-0034] [Reference Citation Analysis]
76 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Nguyen CT, Calderaro J. Immune changes linked to locoregional treatment of hepatocellular carcinoma. Histopathology 2021;79:34-5. [PMID: 34115404 DOI: 10.1111/his.14342] [Reference Citation Analysis]
78 Calderaro J. Dual angiogenesis and PD-1 blockade in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:350-2. [PMID: 32509827 DOI: 10.21037/hbsn.2019.10.37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
80 Sonntag R, Penners C, Kohlhepp M, Haas U, Lambertz D, Kroh A, Cramer T, Ticconi F, Costa IG, Tacke F, Gassler N, Trautwein C, Liedtke C. Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers (Basel) 2021;13:5680. [PMID: 34830835 DOI: 10.3390/cancers13225680] [Reference Citation Analysis]
81 Tietze L, Kessler SM. The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1261. [PMID: 32429417 DOI: 10.3390/cancers12051261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
82 Zhou J, Wang W, Li Q. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. J Exp Clin Cancer Res 2021;40:73. [PMID: 33596985 DOI: 10.1186/s13046-021-01873-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
83 Holczbauer Á, Wangensteen KJ, Shin S. Cellular origins of regenerating liver and hepatocellular carcinoma. JHEP Reports 2022;4:100416. [DOI: 10.1016/j.jhepr.2021.100416] [Reference Citation Analysis]
84 Dinh TA, Utria AF, Barry KC, Ma R, Abou-Alfa GK, Gordan JD, Jaffee EM, Scott JD, Zucman-Rossi J, O'Neill AF, Furth ME, Sethupathy P. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35190728 DOI: 10.1038/s41575-022-00580-3] [Reference Citation Analysis]
85 He Q, Fan B, Du P, Jin Y. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. Front Cell Dev Biol 2022;10:806989. [DOI: 10.3389/fcell.2022.806989] [Reference Citation Analysis]
86 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [PMID: 34853638 DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
87 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
88 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Reference Citation Analysis]
89 Du M, Cai YM, Yin YL, Xiao L, Ji Y. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World J Clin Cases 2022; 10(3): 856-869 [DOI: 10.12998/wjcc.v10.i3.856] [Reference Citation Analysis]
90 Schulien I, Hasselblatt P. Diethylnitrosamine-induced liver tumorigenesis in mice. Methods Cell Biol 2021;163:137-52. [PMID: 33785162 DOI: 10.1016/bs.mcb.2020.08.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Kamimura K, Yokoo T, Abe H, Sakai N, Nagoya T, Kobayashi Y, Ohtsuka M, Miura H, Sakamaki A, Kamimura H, Miyamura N, Nishina H, Terai S. Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E472. [PMID: 32085552 DOI: 10.3390/cancers12020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Cerapio JP, Marchio A, Cano L, López I, Fournié JJ, Régnault B, Casavilca-Zambrano S, Ruiz E, Dejean A, Bertani S, Pineau P. Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry. Oncotarget 2021;12:475-92. [PMID: 33747361 DOI: 10.18632/oncotarget.27890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, Cen B, Wei X, Wei Q, Xie H, Xu X. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res 2021;33:470-9. [PMID: 34584372 DOI: 10.21147/j.issn.1000-9604.2021.04.04] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
95 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
97 Böttcher K, Longato L, Marrone G, Mazza G, Ghemtio L, Hall A, Luong TV, Caruso S, Viollet B, Zucman-Rossi J, Pinzani M, Rombouts K. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. Am J Physiol Gastrointest Liver Physiol 2021;320:G543-56. [PMID: 33406006 DOI: 10.1152/ajpgi.00262.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Mulé S, Galletto Pregliasco A, Tenenhaus A, Kharrat R, Amaddeo G, Baranes L, Laurent A, Regnault H, Sommacale D, Djabbari M, Pigneur F, Tacher V, Kobeiter H, Calderaro J, Luciani A. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. Radiology 2020;295:562-71. [PMID: 32228294 DOI: 10.1148/radiol.2020192230] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
99 Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: An update. World J Hepatol 2021; 13(4): 393-410 [PMID: 33959223 DOI: 10.4254/wjh.v13.i4.393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Hermida M, Cassinotto C, Piron L, Aho-Glélé S, Guillot C, Schembri V, Allimant C, Jaber S, Pageaux GP, Assenat E, Guiu B. Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients. Cancers (Basel) 2020;12:E313. [PMID: 32013112 DOI: 10.3390/cancers12020313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
101 Zheng BH, Ma JQ, Tian LY, Dong LQ, Song GH, Pan JM, Liu YM, Yang SX, Wang XY, Zhang XM, Zhou J, Fan J, Shi JY, Gao Q. The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med 2020;10:45-56. [PMID: 32508015 DOI: 10.1002/ctm2.11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
102 Mou H, Yang QA, Yu L, Wang T, Liu K, Shen R, Pan X, Dai Y, Wan Q, Zhou F, Qian L, Chen D, Yau T, Dong X, Wang X, Wang S. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. J Gastroenterol Hepatol 2021. [PMID: 33656759 DOI: 10.1111/jgh.15475] [Reference Citation Analysis]
103 Calderaro J, Kather JN. Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers. Gut. 2020;. [PMID: 33214163 DOI: 10.1136/gutjnl-2020-322880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
104 Martins-filho SN, Alves VAF. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surg Exp Pathol 2019;2. [DOI: 10.1186/s42047-019-0047-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 2022:S0168-8278(22)00031-9. [PMID: 35143898 DOI: 10.1016/j.jhep.2022.01.018] [Reference Citation Analysis]
106 Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells 2021;10:648. [PMID: 33804045 DOI: 10.3390/cells10030648] [Reference Citation Analysis]
107 Wang H, Jiang Y, Li B, Cui Y, Li D, Li R. Single-Cell Spatial Analysis of Tumor and Immune Microenvironment on Whole-Slide Image Reveals Hepatocellular Carcinoma Subtypes. Cancers (Basel) 2020;12:E3562. [PMID: 33260561 DOI: 10.3390/cancers12123562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ahmad M, Dhasmana A, Harne PS, Zamir A, Hafeez BB. Chemokine Clouding and Liver Cancer Heterogeneity: Does it Impact Clinical Outcomes? Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.015] [Reference Citation Analysis]
109 Qin XS, Zhang CL, Huang ZS. Influence of tumor microenvironment on angiogenesis in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 493-500 [DOI: 10.11569/wcjd.v28.i12.493] [Reference Citation Analysis]
110 Liu Y, Al-Adra DP, Lan R, Jung G, Li H, Yeh MM, Liu YZ. RNA sequencing analysis of hepatocellular carcinoma identified oxidative phosphorylation as a major pathologic feature. Hepatol Commun 2022. [PMID: 35344307 DOI: 10.1002/hep4.1945] [Reference Citation Analysis]
111 Cannella R, Dioguardi Burgio M, Beaufrère A, Trapani L, Paradis V, Hobeika C, Cauchy F, Bouattour M, Vilgrain V, Sartoris R, Ronot M. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Rep 2021;3:100380. [PMID: 34825155 DOI: 10.1016/j.jhepr.2021.100380] [Reference Citation Analysis]
112 Li P, Liang Y, Zeng B, Yang G, Zhu C, Zhao K, Xu Z, Wang G, Han C, Ye H, Liu Z, Zhu Y, Liang C. Preoperative prediction of intra-tumoral tertiary lymphoid structures based on CT in hepatocellular cancer. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110309] [Reference Citation Analysis]
113 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]